Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Vigil™ Augmented Autologous Tumor Cell Immunotherapy in Combination With Nivolumab PD-1 Inhibitor for Patients With Advanced Non-Small Cell Lung Cancer

NCT02639234 is registered in ClinicalTrials.gov with Gradalis, Inc. as lead sponsor.

NCT NCT02639234
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02639234 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Vigil™ Augmented Autologous Tumor Cell Immunotherapy in Combination With Nivolumab PD-1 Inhibitor for Patients With Advanced Non-Small Cell Lung Cancer
Lead sponsor
Gradalis, Inc.
Phase
Phase 2
Overall status
Withdrawn
Start date
March 31, 2016
Completion date
March 31, 2017
Enrollment
0 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced non-small cell lung cancer, lung neoplasms, metastatic non-small cell lung cancer